Policy & Regulation
Merck's Phase 3 trial of sac-TMT meets overall survival endpoint in advanced gastroesophageal cancer
20 November 2026 -

US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Friday that the Phase 3 TroFuse-015 trial evaluating investigational drug sacituzumab tirumotecan (sac-TMT) met its primary endpoint of overall survival (OS) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two previous lines of systemic therapy.

The trial demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with treatment of physician's choice, making sac-TMT the first TROP2-directed antibody-drug conjugate (ADC) to demonstrate an overall survival benefit in this patient population in a global Phase 3 study.

However, the trial did not meet the secondary endpoint of progression-free survival assessed by blinded independent central review. Objective response rates showed a nominal improvement in favour of sac-TMT, and the safety profile remained consistent with previous studies, with no new safety signals identified.

Merck plans to present the findings at an upcoming medical meeting and share the data with regulatory authorities. TroFuse-015 represents the second positive Phase 3 readout from the company's TroFuse development programme, which comprises 18 ongoing global Phase 3 trials evaluating sac-TMT across multiple cancer types and treatment settings.

Login
Username:

Password: